TIM-1 expression is upregulated in several cancers, including renal cell and ovarian carcinomas. It is associated with kidney injury and the shedding of its ectodomain is a predictive biomarker for tumor progression. TIM-1 has very restricted expression in healthy tissues, making it a promising target for antibody mediated therapy. The data were presented in a poster presentation at the American Association of Cancer ResearchCancer Research (AACR) Annual Meeting 2014.
"We believe CDX-014 will be another exciting addition to our clinical pipeline," said Tibor Keler, PhD, Senior Vice President and Chief Scientific Officer of Celldex. "The data presented today confirmconfirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015."
CDX-014 was developed internally by Celldex. A fully human monoclonal antibody specific for extracellular domain of TIM-1 was selected to bind to TIM-1 expressed on a variety of transformed cell lines, including human renal cell and ovarian carcinoma. Internalization studies demonstrated that the antibody was rapidly internalized by cells in vitro and the internalization was confirmed by quantitative imaging flow symmetry. The ADC CDX-014 was produced by the covalent linkage of the anti-TIM-1 antibodies to monomethyl auristatin E (MMAE), a potent cytotoxin. CDX-014 demonstrated in vitro cytostatic or cytotoxic activity against a variety of TIM-1 expressing cell lines, but did not impact TIM-1 negative cell lines. Significant anti-tumor activity was observed in predictive preclinical xenograft models of human renal clear cell carcinoma, human ovarian adenocarcinoma and human lung carcinoma.
..told U all last week the AACR would do it!
Sentiment: Strong Buy
CLDX's science continues to consistently and impressively overachieve. I increasingly fear we are looking at a managed drive down for a hostile. A few months ago, this traded freely near 40. Today, a hostile may steal the company at 40. Unlike many of the recent takeovers that have come out recently, CLDX comes with a robust platform, an extraordinary science team, no debt, $300M cash, and full rights on its pipeline (a pipeline so deep, it consciously shelved a potentially blockbuster...which, again, a suitor would fully own upon purchase). I hope we move up soon, b/c I see CLDX as an absolute game changer on its own. Problem is, Big Pharma knows it, too...and why compete with something you can own?
sumno, there has been past talk how cldx was a acquisition target. If the news coming out of cldx continues this yr to be good ….$35+ by ASCO, $45 + end of yr… then we may see a take over bid of $75+ soon after. All will depend on the news stream this yr and that could set the stage of a bid.
I didn't read any news; been out all day, in fact. But only seven cents down? Shorts are grinding their teeth, thinking they could drive it down further.
Only a matter of time before the bubble starts to rise.
On a further debacle of the rest of the market we have been beaten down enough now the extremely promising prospects and others (we are in the first group) now will resume their rise. This, today was a shot in the gut to Shorts, their ride came across a bit of cement as we closed near even, on a day like today and 300K block purchase into closing, a nice little bolt of lightening was place up their derierres MF's
not really Deutrax imo!
look Deutrax... this in another example of the CLDX way WORKING....and they use the back drop of the AACR to announce 1401 goes into the clinic..it is clear that they intend to develop this Tx too...I see this as a stabilizing force on the current downturn and likely some will come in here and I think they have started yestaerday after taht 15.25 low, I mean I bought some more at that point too and even last night in AH we had some covering at 16+..so that should continue imo!
I think the BUYERS are coming back in now Deu!
Sentiment: Strong Buy